Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

In this article, an overview of lessons from cost-effectiveness analyses of disease-modifying drugs for the treatment of multiple sclerosis is provided. Special attention is paid to the uncertainty in reaching a conclusion from the economic evaluations. If recent debates over multiple sclerosis drugs are any indication, the public's understanding of why one conducts an economic evaluation may be at least as important as the cost-effectiveness estimate from the analysis.

Original languageEnglish (US)
Pages (from-to)537-547
Number of pages11
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume4
Issue number5
DOIs
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

Multiple Sclerosis
Cost-Benefit Analysis
Pharmaceutical Preparations
Uncertainty

Keywords

  • Cost utility
  • Cost-effectiveness
  • Multiple sclerosis
  • Rationing

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

@article{70c631b0f49a4b068c2ab1ff1a311044,
title = "Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis",
abstract = "In this article, an overview of lessons from cost-effectiveness analyses of disease-modifying drugs for the treatment of multiple sclerosis is provided. Special attention is paid to the uncertainty in reaching a conclusion from the economic evaluations. If recent debates over multiple sclerosis drugs are any indication, the public's understanding of why one conducts an economic evaluation may be at least as important as the cost-effectiveness estimate from the analysis.",
keywords = "Cost utility, Cost-effectiveness, Multiple sclerosis, Rationing",
author = "Hoch, {Jeffrey S}",
year = "2004",
month = "10",
doi = "10.1586/14737167.4.5.537",
language = "English (US)",
volume = "4",
pages = "537--547",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis

AU - Hoch, Jeffrey S

PY - 2004/10

Y1 - 2004/10

N2 - In this article, an overview of lessons from cost-effectiveness analyses of disease-modifying drugs for the treatment of multiple sclerosis is provided. Special attention is paid to the uncertainty in reaching a conclusion from the economic evaluations. If recent debates over multiple sclerosis drugs are any indication, the public's understanding of why one conducts an economic evaluation may be at least as important as the cost-effectiveness estimate from the analysis.

AB - In this article, an overview of lessons from cost-effectiveness analyses of disease-modifying drugs for the treatment of multiple sclerosis is provided. Special attention is paid to the uncertainty in reaching a conclusion from the economic evaluations. If recent debates over multiple sclerosis drugs are any indication, the public's understanding of why one conducts an economic evaluation may be at least as important as the cost-effectiveness estimate from the analysis.

KW - Cost utility

KW - Cost-effectiveness

KW - Multiple sclerosis

KW - Rationing

UR - http://www.scopus.com/inward/record.url?scp=5444237090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5444237090&partnerID=8YFLogxK

U2 - 10.1586/14737167.4.5.537

DO - 10.1586/14737167.4.5.537

M3 - Review article

C2 - 19807547

AN - SCOPUS:5444237090

VL - 4

SP - 537

EP - 547

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 5

ER -